article · Journal of Advances in Microbiology
Escherichia coli that produce the Shiga toxin (STEC) has become one of the most significant foodborne pathogens linked to serious illnesses. Our study was aimed to detect the existence, antimicrobial profiles, and virulence repertoire of different STEC serotypes from fecal samples of dairy cattle.
 We collected 19 fecal samples (12 diarrheic and 7 non-diarrheic) from dairy cattle. E. coli isolation and identification were performed. Shiga toxins genes were detected and the antimicrobial resistance was investigated.
 E. coli was detected at the rate of 13/19 (68.4%) from the fecal samples. The frequency of Stx2a represented 12/13 (92.3%), Stx2 represented 3/13 (23.14%), and Stx1d, Stx2f, Stx2g, and eae represented 2/13 (15.4%). While the virulence genes Stx1, Stx1c, Stx2c, Stx2d, Stx2e, and ehxA represented 0/13 (0%). The most effective antimicrobials were tulathithromycin 30 (53.84%) followed by ceftiofur 30 and marbofloxacin (46.16%), amikacin (15.38%), and the least resistance was recorded for nalidixic acid and oxytetracycline (7.70%). The resistant antibiotics with percentages reached to 100% were Amoxicillin/ Clavulanic acid, Ceftriaxone, Ciprofloxacin, Doxycycline, Erythromycin, Gentamicin, Ninezolid, Nitrofurantoin, Penicillin G, Streptomycin, and Trimethoprim/Sulfamethoxazole, followed by chloramphenicol, nalidixic acid, oxytetracycline, and Tylosine (92.30%), Amikacin and Ampicillin (84.62%), Ceftiofur (23.07%), Marbofloxacin (15.38%) and Tulathithromycin 30 (7.70%).
 The findings demonstrated that E. coli that are resistant to numerous groups of antimicrobials spread through feces and may pose a risk to human and animal health.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.9734/jamb/2024/v24i1788
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.